STOCK TITAN

Clearside Biomedical to Report Second Quarter 2021 Financial Results and Provide Corporate Update on Tuesday, August 10, 2021

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences earnings
Rhea-AI Summary

Clearside Biomedical, Inc. (NASDAQ:CLSD) will report its second quarter 2021 financial results on August 10, 2021, post-market. A webcast and conference call will be held at 4:30 p.m. ET to discuss these results and provide an update on the company’s initiatives. Clearside specializes in treatments for severe eye diseases, utilizing its proprietary SCS Microinjector® to deliver therapies directly to affected areas within the eye. More information can be accessed on their website.

Positive
  • None.
Negative
  • None.

ALPHARETTA, Ga., July 27, 2021 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases, announced today that its second quarter 2021 financial results will be reported on Tuesday, August 10, 2021 after the close of the financial markets. Management will host a webcast and conference call at 4:30 p.m. Eastern Time to discuss the results and provide a corporate update.

The live and archived webcast may be accessed on the Clearside website under the Investors section: Events and Presentations. The live call can be accessed by dialing (844) 263-8310 (domestic) or (213) 358-0959 (international) and entering conference code: 7785213. An archive of the webcast will be available for three months.

About Clearside Biomedical

Clearside Biomedical, Inc. is a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases. Clearside’s proprietary SCS Microinjector® targets the suprachoroidal space (SCS®) and offers unique access to the macula, retina and choroid where sight-threatening disease often occurs. The Company’s SCS injection platform is an inherently flexible, in-office, non-surgical procedure, intended to provide targeted delivery to the site of disease and to work with both established and new formulations of medications. For more information, please visit www.clearsidebio.com.

Source: Clearside Biomedical, Inc.


FAQ

When will Clearside Biomedical report its second quarter 2021 financial results?

Clearside Biomedical will report its second quarter 2021 financial results on August 10, 2021.

What time is the Clearside Biomedical conference call scheduled?

The conference call for Clearside Biomedical is scheduled for 4:30 p.m. Eastern Time on August 10, 2021.

How can I access the webcast for Clearside Biomedical's financial results?

The webcast can be accessed on Clearside Biomedical's website under the Investors section.

What is the focus of Clearside Biomedical?

Clearside Biomedical focuses on developing treatments for serious back of the eye diseases.

Clearside Biomedical, Inc.

NASDAQ:CLSD

CLSD Rankings

CLSD Latest News

CLSD Stock Data

66.74M
70.22M
7.39%
23.17%
2.35%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
ALPHARETTA